Hong Kong · Delayed Price · Currency is HKD Sinopharm Group Statistics
Total Valuation
Sinopharm Group has a market cap or net worth of HKD 57.92 billion. The enterprise value is 162.27 billion.
| Market Cap | 57.92B |
| Enterprise Value | 162.27B |
Important Dates
The last earnings date was Thursday, August 21, 2025.
| Earnings Date | Aug 21, 2025 |
| Ex-Dividend Date | Jun 16, 2025 |
Share Statistics
Sinopharm Group has 3.12 billion shares outstanding. The number of shares has decreased by -0.48% in one year.
| Current Share Class | 1.34B |
| Shares Outstanding | 3.12B |
| Shares Change (YoY) | -0.48% |
| Shares Change (QoQ) | +0.98% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 28.18% |
| Float | 1.34B |
Valuation Ratios
The trailing PE ratio is 7.74 and the forward PE ratio is 6.84. Sinopharm Group's PEG ratio is 1.50.
| PE Ratio | 7.74 |
| Forward PE | 6.84 |
| PS Ratio | 0.09 |
| PB Ratio | 0.41 |
| P/TBV Ratio | 0.75 |
| P/FCF Ratio | 3.01 |
| P/OCF Ratio | 2.87 |
| PEG Ratio | 1.50 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.47, with an EV/FCF ratio of 8.42.
| EV / Earnings | 21.74 |
| EV / Sales | 0.26 |
| EV / EBITDA | 6.47 |
| EV / EBIT | 8.02 |
| EV / FCF | 8.42 |
Financial Position
The company has a current ratio of 1.34, with a Debt / Equity ratio of 0.72.
| Current Ratio | 1.34 |
| Quick Ratio | 1.07 |
| Debt / Equity | 0.72 |
| Debt / EBITDA | 4.30 |
| Debt / FCF | 5.31 |
| Interest Coverage | 6.87 |
Financial Efficiency
Return on equity (ROE) is 7.83% and return on invested capital (ROIC) is 4.84%.
| Return on Equity (ROE) | 7.83% |
| Return on Assets (ROA) | 2.54% |
| Return on Invested Capital (ROIC) | 4.84% |
| Return on Capital Employed (ROCE) | 12.30% |
| Revenue Per Employee | 5.83M |
| Profits Per Employee | 68,964 |
| Employee Count | 108,217 |
| Asset Turnover | 1.36 |
| Inventory Turnover | 7.93 |
Taxes
In the past 12 months, Sinopharm Group has paid 4.11 billion in taxes.
| Income Tax | 4.11B |
| Effective Tax Rate | 27.56% |
Stock Price Statistics
The stock price has increased by +8.79% in the last 52 weeks. The beta is 0.58, so Sinopharm Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.58 |
| 52-Week Price Change | +8.79% |
| 50-Day Moving Average | 18.96 |
| 200-Day Moving Average | 19.37 |
| Relative Strength Index (RSI) | 41.55 |
| Average Volume (20 Days) | 5,768,896 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sinopharm Group had revenue of HKD 630.98 billion and earned 7.46 billion in profits. Earnings per share was 2.40.
| Revenue | 630.98B |
| Gross Profit | 46.86B |
| Operating Income | 18.92B |
| Pretax Income | 14.92B |
| Net Income | 7.46B |
| EBITDA | 21.16B |
| EBIT | 18.92B |
| Earnings Per Share (EPS) | 2.40 |
Balance Sheet
The company has 51.67 billion in cash and 102.23 billion in debt, giving a net cash position of -50.56 billion or -16.20 per share.
| Cash & Cash Equivalents | 51.67B |
| Total Debt | 102.23B |
| Net Cash | -50.56B |
| Net Cash Per Share | -16.20 |
| Equity (Book Value) | 141.87B |
| Book Value Per Share | 28.23 |
| Working Capital | 103.13B |
Cash Flow
In the last 12 months, operating cash flow was 20.19 billion and capital expenditures -926.69 million, giving a free cash flow of 19.27 billion.
| Operating Cash Flow | 20.19B |
| Capital Expenditures | -926.69M |
| Free Cash Flow | 19.27B |
| FCF Per Share | 6.17 |
Margins
Gross margin is 7.43%, with operating and profit margins of 3.00% and 1.18%.
| Gross Margin | 7.43% |
| Operating Margin | 3.00% |
| Pretax Margin | 2.36% |
| Profit Margin | 1.18% |
| EBITDA Margin | 3.35% |
| EBIT Margin | 3.00% |
| FCF Margin | 3.05% |
Dividends & Yields
This stock pays an annual dividend of 0.74, which amounts to a dividend yield of 4.00%.
| Dividend Per Share | 0.74 |
| Dividend Yield | 4.00% |
| Dividend Growth (YoY) | -22.70% |
| Years of Dividend Growth | 4 |
| Payout Ratio | 36.97% |
| Buyback Yield | 0.48% |
| Shareholder Yield | 4.48% |
| Earnings Yield | 12.89% |
| FCF Yield | 33.27% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sinopharm Group has an Altman Z-Score of 2.08 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.08 |
| Piotroski F-Score | 5 |